Search Results - "Goldberg, Stefan V"

Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials by Moro, Ruth N, Scott, Nigel A, Vernon, Andrew, Tepper, Naomi K, Goldberg, Stefan V, Schwartzman, Kevin, Leung, Chi-Chiu, Schluger, Neil W, Belknap, Robert W, Chaisson, Richard E, Narita, Masahiro, Machado, Elizabeth S, Lopez, Marta, Sanchez, Jorge, Villarino, Margarita E, Sterling, Timothy R

“…Data are limited regarding the safety of 12-dose once-weekly isoniazid (H, 900 mg) plus rifapentine (P, 900 mg) (3HP) for latent infection treatment during…”
Get full text

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis by Dorman, Susan E, Nahid, Payam, Kurbatova, Ekaterina V, Phillips, Patrick P.J, Bryant, Kia, Dooley, Kelly E, Engle, Melissa, Goldberg, Stefan V, Phan, Ha T.T, Hakim, James, Johnson, John L, Lourens, Madeleine, Martinson, Neil A, Muzanyi, Grace, Narunsky, Kim, Nerette, Sandy, Nguyen, Nhung V, Pham, Thuong H, Pierre, Samuel, Purfield, Anne E, Samaneka, Wadzanai, Savic, Radojka M, Sanne, Ian, Scott, Nigel A, Shenje, Justin, Sizemore, Erin, Vernon, Andrew, Waja, Ziyaad, Weiner, Marc, Swindells, Susan, Chaisson, Richard E

“…In this phase 3 trial for the treatment of tuberculosis, a 4-month rifapentine-based regimen containing moxifloxacin was noninferior to a standard 6-month…”
Get full text

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid by Villarino, M Elsa, Scott, Nigel A, Weis, Stephen E, Weiner, Marc, Conde, Marcus B, Jones, Brenda, Nachman, Sharon, Oliveira, Ricardo, Moro, Ruth N, Shang, Nong, Goldberg, Stefan V, Sterling, Timothy R

“…Three months of a once-weekly combination of rifapentine and isoniazid for treatment of latent tuberculosis infection is safe and effective for persons 12…”
Get more information

Evaluation of a High-Throughput Repetitive-Sequence-Based PCR System for DNA Fingerprinting of Mycobacterium tuberculosis and Mycobacterium avium Complex Strains by CANGELOSI, Gerard A, FREEMAN, Robert J, LEWIS, I. Kaeryn N, LIVINGSTON-ROSANOFF, Devon, SHAH, Ketan S, MILAN, Sparrow Joy, GOLDBERG, Stefan V

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada by Moro, Ruth N., Borisov, Andrey S., Saukkonen, Jussi, Khan, Awal, Sterling, Timothy R., Villarino, M. Elsa, Scott, Nigel A., Shang, Nong, Kerrigan, Amy, Goldberg, Stefan V.

“…Background. Overall rates of noncompletion of treatment (NCT) for latent tuberculosis infection (LTBI) in the PREVENT TB trial were 18% for 3 months of…”
Get full text

A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials by Kurbatova, Ekaterina V, Phillips, Patrick P J, Dorman, Susan E, Sizemore, Erin E, Bryant, Kia E, Purfield, Anne E, Ricaldi, Jessica, Brown, Nicole E, Johnson, John L, Wallis, Carole L, Akol, Joseph P, Ocheretina, Oksana, Van Hung, Nguyen, Mayanja-Kizza, Harriet, Lourens, Madeleine, Dawson, Rodney, Nhung, Nguyen Viet, Pierre, Samuel, Musodza, Yeukai, Shenje, Justin, Badal-Faesen, Sharlaa, Vilbrun, Stalz Charles, Waja, Ziyaad, Peddareddy, Lakshmi, Scott, Nigel A, Yuan, Yan, Goldberg, Stefan V, Swindells, Susan, Chaisson, Richard E, Nahid, Payam

“…We developed a standardized method, possible poor treatment response (PPTR), to help ascertain efficacy endpoints in Study S31/A5349 (NCT02410772), an…”
Get full text

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial by Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Goldberg, Stefan V., Bozeman, Lorna, Burman, William J., Chang, Kwok-Chiu, Chen, Michael, Cotton, Mark, Dooley, Kelly E., Engle, Melissa, Feng, Pei-Jean, Fletcher, Courtney V., Ha, Phan, Heilig, Charles M., Johnson, John L., Lessem, Erica, Metchock, Beverly, Miro, Jose M., Nhung, Nguyen Viet, Pettit, April C., Phillips, Patrick P.J., Podany, Anthony T., Purfield, Anne E., Robergeau, Kathleen, Samaneka, Wadzanai, Scott, Nigel A., Sizemore, Erin, Vernon, Andrew, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.

“…Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent…”
Get full text

Optimizing drug inventory management with a web-based information system: The TBTC Study 31/ACTG A5349 experience by Scott, Nigel A., Lee, Kara K., Sadowski, Claire, Kurbatova, Ekaterina V., Goldberg, Stefan V., Nsubuga, Pheona, Kitshoff, Rene, Whitelaw, Colleen, Thuy, Hanh Nguyen, Batra, Kumar, Allen-Blige, Cynthia, Davis, Howard, Kim, Jay, Phan, Mimi, Fedrick, Pamela, Chiu, Kuo Wei, Heilig, Charles M., Sizemore, Erin

“…Efficient management of study drug inventory shipments is critical to keep research sites enrolling into multisite clinical treatment trials. A standard manual…”
Get full text

Expanded Geographical Distribution of the N Family of Mycobacterium tuberculosis Strains within the United States by MILAN, S. Joy, HAUGE, Kirsten A, KUREPINA, Natalia E, LOFY, Kathryn H, GOLDBERG, Stefan V, NARITA, Masahiro, NOLAN, Charles M, MCELROY, Peter D, KREISWIRTH, Barry N, CANGELOSI, Gerard A

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen by Hedges, Kimberley N Chapman, Borisov, Andrey S, Saukkonen, Jussi J, Scott, Nigel A, Hecker, Emily J, Bozeman, Lorna, Dukes Hamilton, Carol, Kerrigan, Amy, Bessler, Patricia, Moreno-Martinez, Antonio, Arevalo, Bert, Goldberg, Stefan V

“…Background/aims Efficient recruitment of eligible participants, optimizing time and sample size, is a crucial component in conducting a successful clinical…”
Get full text

Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection by Jereb, John A, Goldberg, Stefan V, Powell, Krista, Villarino, M. Elsa, LoBue, Philip

“…Preventing tuberculosis (TB) by treating latent Mycobacterium tuberculosis infection (LTBI) is a cornerstone of the U.S. strategy for TB elimination. Three…”
Get full text

Rifamycin Treatment of Tuberculosis in a Patient Receiving Atenolol: Less Interaction with Rifabutin than with Rifampin by Goldberg, Stefan V., Hanson, Daniel, Peloquin, Charles A.

Get full text

Hepatotoxicity Associated With Isoniazid Preventive Therapy: A 7-Year Survey From a Public Health Tuberculosis Clinic by Nolan, Charles M, Goldberg, Stefan V, Buskin, Susan E

“…CONTEXT Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated because of the risk of hepatotoxicity. The frequency of…”
Get full text

What is the most reliable solid culture medium for tuberculosis treatment trials? by Joloba, Moses L, Johnson, John L, Feng, Pei-Jean I, Bozeman, Lorna, Goldberg, Stefan V, Morgan, Karen, Gitta, Phineas, Boom, Henry W, Heilig, Charles M, Mayanja-Kizza, Harriet, Eisenach, Kathleen D

“…Summary We conducted a prospective study to determine which solid medium is the most reliable overall and after two months of therapy to detect Mycobacterium…”
Get full text

The association between symptoms and microbiologically defined response to tuberculosis treatment by Hales, Craig M, Heilig, Charles M, Chaisson, Richard, Leung, Chi Chiu, Chang, Kwok Chiu, Goldberg, Stefan V, Gordin, Fred, Johnson, John L, Muzanyi, Grace, Saukkonen, Jussi, Vernon, Andrew, Villarino, M Elsa, Burman, William J

“…The lack of consistent associations between clinical outcomes and microbiological responses to therapy for some infectious diseases has raised questions about…”
Get full text

How we determined the most reliable solid medium for studying treatment of tuberculosis by Heilig, Charles M, Feng, Pei-Jean I, Joloba, Moses L, Johnson, John L, Morgan, Karen, Gitta, Phineas, Boom, W. Henry, Mayanja-Kizza, Harriet, Eisenach, Kathleen D, Bozeman, Lorna, Goldberg, Stefan V

“…Summary Phase 2 clinical trials for tuberculosis (TB) treatment require reliable culture methods to determine presence or absence of Mycobacterium tuberculosis…”
Get full text

Evaluation of the Informed Consent Process of a Multicenter Tuberculosis Treatment Trial by Chapman, Kimberley N., Pevzner, Eric, Mangan, Joan M., Breese, Peter, Lamunu, Dorcas, Shrestha-Kuwahara, Robin, Nakibali, Joseph G., Goldberg, Stefan V.

“…Background: Ethical principles obligate researchers to maximize study participants' comprehension during the informed consent process for clinical trials. A…”
Get full text

Pooling tides: the convergence of migration, congregation, and tuberculosis [Editorial] by Goldberg, Stefan V.

Get full text

Tuberculosis prevention among foreign-born persons in Seattle-King County, Washington by WELLS, C. D, ZUBER, P. L. F, NOLAN, C. M, BINKIN, N. J, GOLDBERG, S. V

“…The purpose of this study was to evaluate the outcomes of classified immigrant and refugee (I&R) screening and of contact investigation (CI) of foreign-born TB…”
Get full text

Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis by GOLDBERG, S. V, DUCHIN, J. S, SHIELDS, T, NOLAN, C. M

“…Standard preventive therapy for inactive pulmonary tuberculosis (TB) is 12 mo of isoniazid. Shorter multiple-drug preventive regimens have been proposed. From…”
Get full text